Abbott Laboratories (ABT) Other Accumulated Expenses (2009 - 2026)

Abbott Laboratories has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $6.4 billion for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $6.4 billion, up 13.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 billion (up 13.91% YoY), and the FY2025 annual result was $5.8 billion, up 13.01% from the prior year.
• Other Accumulated Expenses came in at $6.4 billion for Q1 2026 at Abbott Laboratories, up from $5.8 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $6.4 billion in Q1 2026 to a low of $5.1 billion in Q2 2024.
• The 5-year median for Other Accumulated Expenses is $5.5 billion (2022), against an average of $5.5 billion.
• Across the five-year window, Other Accumulated Expenses slipped 9.34% in 2024 and gained 13.91% in 2026, its largest moves.
• Abbott Laboratories' Other Accumulated Expenses stood at $5.8 billion in 2022, then slipped by 7.24% to $5.4 billion in 2023, then decreased by 5.15% to $5.1 billion in 2024, then gained by 13.01% to $5.8 billion in 2025, then advanced by 9.76% to $6.4 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $6.4 billion (Q1 2026), $5.8 billion (Q4 2025), and $5.9 billion (Q3 2025), per Business Quant data.